2009–10 Calgary Flames season

Enveric Biosciences and University of Calgary Collaborate on a Groundbreaking Clinical Trial for EVM-101 in Cancer Related Distress

Retrieved on: 
Thursday, February 17, 2022

Approximately 50% of cancer patients report clinical levels of psychological distress having depressed mood, anxiety, demoralization, stress-induced clinical manifestations, and reduced quality of life1.

Key Points: 
  • Approximately 50% of cancer patients report clinical levels of psychological distress having depressed mood, anxiety, demoralization, stress-induced clinical manifestations, and reduced quality of life1.
  • Up to 40% of cancer patients meet the criteria for a mood disorder requiring treatment2.
  • The EVM-101 study will directly assess the core features of CRD that are most affected and amenable to improvement following a psilocybin-based treatment.
  • Patient enrollment in the clinical trial is expected to begin late in 2022 or early in 2023.